A Phase I, Double-Blind, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 31 May 2018
At a glance
- Drugs NTM 1634 (Primary)
- Indications Botulism; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Severe acute respiratory syndrome
- Focus Adverse reactions
- Sponsors Ology Bioservices
- 03 Apr 2018 Status changed from active, no longer recruiting to completed.
- 02 Oct 2017 According to a Ology Bioservices media release, Nanotherapeutics changed its name to Ology Bioservices.
- 05 Jun 2017 Status changed from recruiting to active, no longer recruiting.